A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. The metric has seen a significant loss of -17.73% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -11.01%. Over the past 30 days, the price of CRSP has fallen by 1.54%. And in the last five days, it has surged by 0.64%.
CRISPR Therapeutics AG ‘s stock market performance has been somewhat erratic. The company’s stock reached a 1-year high price of $91.10 on 02/22/24, while the lowest value for the same period was recorded at $43.42 on 09/06/24.
52-week price history of CRSP Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. CRISPR Therapeutics AG’s current trading price is -43.47% away from its 52-week high, while its distance from the 52-week low is 18.61%. The stock’s price range during this period has varied between$43.42 and $91.10. The CRISPR Therapeutics AG’s shares, which operate in the Healthcare, saw a trading volume of around 0.62 million for the day, a figure considerably lower than their average daily volume of 1.4 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
CRISPR Therapeutics AG (CRSP) has experienced a quarterly rise of 14.78% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 4.40B and boasts a workforce of 407 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 49.09, with a change in price of -8.30. Similarly, CRISPR Therapeutics AG recorded 1,313,448 in trading volume during the last 100 days, posting a change of -13.72%.
CRSP’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for CRSP stands at 0.12. Similarly, the long-term debt-to-equity ratio is also 0.11.
CRSP Stock Stochastic Average
CRISPR Therapeutics AG’s raw stochastic average for the past 50 days is presently 52.92%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 49.20%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 40.07% and 43.15%, respectively.